Article
Recharacterization of RSL3 reveals that the selenoproteome is a druggable target in…
medRxiv · 2024 · DeAngelo, S. L.; Dziechciarz, S.; Solanki, S.; Shin, M.; Zhao, L.; Balia, A.; El-Derany, M. O.; Das, N. K.; Castillo, C.; Bell, H. N.; Paulo, J. A.; Zhang, Y.; Rossiter, N. J.; McCulla, E. C.; He, J.; Talukder, I.; Schafer, Z. T.; Neamati, N.; Mancias, J. D.; Koutmos, M.; Shah, Y. M.
Key facts
| Title | Recharacterization of RSL3 reveals that the selenoproteome is a druggable target in colorectal cancer |
|---|---|
| First author | DeAngelo, S. L.; Dziechciarz, S.; Solanki, S.; Shin, M.; Zhao, L.; Balia, A.; El-Derany, M. O.; Das, N. K.; Castillo, C.; Bell, H. N.; Paulo, J. A.; Zhang, Y.; Rossiter, N. J.; McCulla, E. C.; He, J.; Talukder, I.; Schafer, Z. T.; Neamati, N.; Mancias, J. D.; Koutmos, M.; Shah, Y. M. |
| Journal | medRxiv |
| Published | Apr 2, 2024 |
| DOI | 10.1101/2024.03.29.587381 |
| Devices mentioned | K073490, K842496 |
| Product codes mentioned | CFN, JXR |
At a glance
- 1–9 FDA submissions mentioned
- 1–9 Product codes mentioned
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About Literature
Peer-reviewed and preprint literature indexed by Orca1 and linked to the FDA submissions and product codes each article mentions. Only bibliographic details are shown here.
Source: Publisher and PubMed metadata; device mentions identified by Orca1